NasdaqGS:MRNABiotechs
Moderna (MRNA): Reassessing Valuation After Recent Share Price Rebound and Stabilizing Revenue Trends
Moderna (MRNA) has been drifting lower this year, even as its pipeline and revenue trends show some signs of stabilization. That disconnect is what has put the stock back on investors radars.
See our latest analysis for Moderna.
At around $29.46, the recent 90 day share price return of 25.31% contrasts with a still weak 1 year total shareholder return of negative 29.57%. This suggests tentative momentum as investors reassess Moderna’s long term pipeline potential.
If Moderna’s rebound has you...